Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a commercial-stage biopharmaceutical company whose news flow is closely tied to its eye care franchise and lotilaner-based pipeline. The company’s lead product, XDEMVY (lotilaner ophthalmic solution) 0.25%, is FDA approved in the United States for the treatment of Demodex blepharitis, and many recent announcements highlight its commercial performance and adoption among eye care professionals.
News updates for Tarsus commonly include quarterly financial results that detail net product sales of XDEMVY, bottles delivered to patients, and spending on research and development and selling, general and administrative activities. These releases often discuss commercial trends, such as prescription growth, direct-to-consumer advertising efforts, and coverage across commercial, Medicare, and Medicaid plans, as described by the company.
Investors and observers can also expect regular items on the advancement of Tarsus’ pipeline programs. The company provides updates on planned and ongoing Phase 2 studies of TP-04, an investigational lotilaner ophthalmic gel for the potential treatment of ocular rosacea, and TP-05, an investigational oral lotilaner tablet for the potential prevention of Lyme disease. In addition, Tarsus frequently announces participation in healthcare and ophthalmology-focused investor conferences, along with details on live webcasts and replay availability.
This news page aggregates these company-issued press releases and related coverage in one place, making it easier to review financial updates, clinical development milestones, and investor events associated with the TARS stock. Users interested in the evolution of XDEMVY, the progress of TP-04 and TP-05, and Tarsus’ broader category-creation strategy in eye care and infectious disease prevention can monitor this feed for ongoing developments.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced management will participate in upcoming investor conferences in early March 2026. Presentations are scheduled at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 11:30 a.m. PT / 2:30 p.m. ET and at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026 at 9:30 a.m. PT / 12:30 p.m. ET.
Live webcasts and event details are available on the company website. Replays will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported full-year 2025 net product sales for XDEMVY of $451.4 million (up >150% YoY) and Q4 sales of $151.7 million. The company delivered ~400,000 bottles in 2025, maintains >90% payer coverage, and ended Year‑end cash of $417.3 million. Pipeline progress includes a Phase 2 start for TP-04 and a planned TP-05 Phase 2 in Q2 2026.
Management expects XDEMVY peak sales potential >$2 billion and noted ongoing regulatory paths in Europe, Japan, and Greater China.
Tarsus Pharmaceuticals (NASDAQ: TARS) appointed David E. I. Pyott, former Allergan CEO, to its Board of Directors on February 18, 2026.
Mr. Pyott brings 17 years of leadership at Allergan, growing sales from about $1 billion to more than $7 billion, and experience across R&D, product development and commercial execution to support XDEMVY and the pipeline.
Tarsus (NASDAQ: TARS) will report fourth quarter and full year 2025 financial results on Monday, February 23, 2026. A live webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET, with a recorded replay available on the company website and archived for about 90 days.
The company will provide a corporate update during the call; investors can access the live webcast via the company’s investor site.
Tarsus (NASDAQ:TARS) said management will participate in a fireside chat at BTIG 5th Annual Ophthalmology Day on Monday, December 1, 2025 at 10:45 a.m. PT / 1:45 p.m. ET.
A live webcast will be available on the events section of the Tarsus website, and a replay will be posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ:TARS) management will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Tuesday, November 11, 2025 at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast will be available and replays will be posted on the company's events page within 48 hours and archived for a limited time.
Tarsus (NASDAQ: TARS) reported third quarter 2025 results with $118.7 million of XDEMVY net product sales, up ~147% YoY, driven by >103,000 bottles delivered and weekly multi-patient prescribers growing ~30% vs Q2 2025. Coverage exceeds 90% across commercial, Medicare and Medicaid, with a gross-to-net discount of 44.7%. Net loss narrowed to $12.6 million (EPS $(0.30)) from $(23.4) million a year earlier. Cash, cash equivalents and marketable securities were $401.8 million at September 30, 2025. Pipeline and milestones include a Phase 2 TP-04 ocular rosacea study starting Dec 2025 (topline by year-end 2026) and a planned TP-05 Lyme prevention study in 2026. Management will host a conference call Nov 4, 2025 at 1:30 p.m. PT / 4:30 p.m. ET.
Tarsus (NASDAQ: TARS) will report third quarter 2025 financial results on Tuesday, November 4, 2025. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET to present results and a corporate update.
Participants may access the live webcast online; a recorded version will be posted on the company website shortly after the call and archived for approximately 90 days.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced its participation in two upcoming investor conferences in September 2025. Management will present at the Wells Fargo 20th Annual Healthcare Conference on September 3rd at 9:30 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 9th at 10:30 a.m. ET.
Investors can access live webcasts of both presentations through the events section of the Tarsus website. Replay recordings will be available within 48 hours and archived for a limited time.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported record Q2 2025 financial results, achieving $102.7 million in net product sales for XDEMVY®, a 152% increase year-over-year. The company distributed approximately 91,000 bottles to patients during the quarter, with over 90% coverage across commercial, Medicare, and Medicaid lives.
The company's Direct-To-Consumer campaign has significantly boosted performance, with consumer awareness of XDEMVY more than tripling and website engagement up 400% since early 2025. More than 20,000 Eye Care Professionals are now prescribing XDEMVY, exceeding the company's target of 15,000.
Despite strong sales growth, Tarsus reported a net loss of $20.3 million ($0.48 per share) for Q2 2025, improved from a $33.3 million loss in Q2 2024. The company maintains a strong cash position of $381.1 million as of June 30, 2025.